SEC Form 4 · accession 0001209191-16-142490
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David John King
Officer — See Remarks
Period of report
Sep 21, 2016
Accepted (ET)
Sep 22, 2016 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.29 | Sep 21, 2016 | A | 145,000 | A | — | Sep 21, 2026 | Common Stock | 145,000 | 145,000 | D |
Explanation of responses
- F11/4 of the shares subject to this option shall vest and become exercisable on September 21, 2017, and the remainder shall thereafter vest in 36 equal monthly installments, such that this option is fully exercisable on September 21, 2020. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Remarks
Senior Vice President, Research